Author:
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 579 | 316 | 33 |
| Full Text Views | 7 | 1 | 0 |
| PDF Downloads | 3 | 2 | 0 |
Astiban® in Schistosomiasis Mansoni: A Controlled Therapeutic Trial in a Nonendemic Area
Mahfouz H. Zaki
Mahfouz H. Zaki
Columbia School of Public Health and Administrative Medicine, and the New York City Health Department
Search for other papers by Mahfouz H. Zaki in
Current site
Google Scholar
PubMed
Search for other papers by Mahfouz H. Zaki in
Current site
Google Scholar
PubMed
Howard B. Shookhoff
Howard B. Shookhoff
Columbia School of Public Health and Administrative Medicine, and the New York City Health Department
Search for other papers by Howard B. Shookhoff in
Current site
Google Scholar
PubMed
Search for other papers by Howard B. Shookhoff in
Current site
Google Scholar
PubMed
Max Sterman
Max Sterman
Columbia School of Public Health and Administrative Medicine, and the New York City Health Department
Search for other papers by Max Sterman in
Current site
Google Scholar
PubMed
Search for other papers by Max Sterman in
Current site
Google Scholar
PubMed
Stanley De Ramos
Stanley De Ramos
Columbia School of Public Health and Administrative Medicine, and the New York City Health Department
Search for other papers by Stanley De Ramos in
Current site
Google Scholar
PubMed
Search for other papers by Stanley De Ramos in
Current site
Google Scholar
PubMed
Summary
One hundred and thirty-five patients suffering from schistosomiasis mansoni were divided into two groups at random. An experimental group of 69 patients was treated with a 20-ml course of a 10 percent solution of antimony dimercaptosodium succinate (TWSb/6 or Astiban®) over a 4- to 5-day period, while a control group of 66 patients was treated with an 80-ml course of 6.3 percent solution of antimony pyrocatechol sodium sulphonate (stibophen or Fuadin®) administered over a 6- to 7-week period.
The two drugs were moderately tolerated. Vomiting and rashes and/or pruritus were frequently encountered in the Astiban group while joint pains were a prominent feature during Fuadin therapy.
The cure rates obtained after a follow-up period of at least four months involving six stool examinations were 79.6 percent and 80.4 percent in the Astiban and Fuadin groups, respectively.
Under the existing conditions in New York City, Astiban has proved to be a potent schistosomicidal drug which can be applied with a reasonable degree of safety on an outpatient basis in mass therapy.
Author Notes
Assistant Professor, Department of Environmental Medicine and Community Health, State University of New York, N. Y.
Chief, Tropical Disease Division, New York City Health Department.
Physician in Charge, Washington Heights Tropical Disease Clinic, New York City.
Public Health Physician (Epidemiologist), New York City Health Department.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 579 | 316 | 33 |
| Full Text Views | 7 | 1 | 0 |
| PDF Downloads | 3 | 2 | 0 |